bioRxivMicrobiology
Diversification of Nucleoside Analogues as Potent Antiviral Drug Leads
S. Scheeff, Y. Wang, M.-Y. Lyu, B. Nasiri Ahmadabadi, S. C. K. Hau, T. K. C. Hui, Y. Zhang, Z. Zuo, R. W. Y. Chan, B. W.-L. Ng
Abstract
Nucleoside analogues are potent antiviral agents, but the continuous emergence of pathogenic viruses demands novel and diverse structures. Herein, we have created a diversified library of highly bioactive and non-cytotoxic nucleoside analogues featuring an unprecedented carbobicyclic core that mimics natural ribonucleoside conformation. These regio- and stereo-divergent analogues exhibit up to 16-fold greater antiviral efficacy than the FDA-approved antiviral, ribavirin. Importantly, the carbobicyclic core structure is critical for the potent antiviral efficacy, thus opening up ample opportunities for further lead optimization and mechanistic investigations. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=108 SRC="FIGDIR/small/545395v2_ufig1.gif" ALT="Figure 1"> View larger version (20K): org.highwire.dtl.DTLVardef@fbd078org.highwire.dtl.DTLVardef@3399a9org.highwire.dtl.DTLVardef@1ad5fcborg.highwire.dtl.DTLVardef@16c2f3d_HPS_FORMAT_FIGEXP M_FIG C_FIG
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural basis for repurpose and design of nucleoside drugs for treating COVID-19
- The Role of Ribose Modifications on the Structural Stability of Nucleotide Analogs with α-thiotriphosphate at the Active Site of SARS-CoV-2 RdRp
Yongfang Li, Shiling Yuan·bioRxiv·Apr 11, 2025
- A Library of Nucleotide Analogues Terminate RNA Synthesis Catalyzed by Polymerases of Coronaviruses Causing SARS and COVID-19
S. Jockusch, C. Tao, … J. Ju·bioRxiv·Apr 23, 2020
- Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection
D. Schultz, R. Johnson, … S. Cherry·bioRxiv·Jun 24, 2021
- The Impact of SARS-CoV-2 nsp14 Proofreading on Nucleoside Antiviral Activity: Insights from Genetic and Pharmacological Investigations
Ju-Yi Peng, Frederick C. Lahser, … Dai Wang·bioRxiv·Jul 24, 2024
- Targeted redesign of suramin analogs for novel antimicrobial lead development
D. Dey, S. Ramakumar, G. L. Conn·Journal of Chemical Information and ModelingPeer-reviewed·Sep 13, 2021